cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25934/00006732
title: Decision Tree Model for Dose Selection in Non-valvular Atrial Fibrillation Patients

description: Stroke, which results from the disruption of focal cerebral blood supply, remains a leading cause of death and disability worldwide. Various subtypes of strokes like cardio-embolic (a clot formed in another part of the body which travels to the brain and causes a blockage) or thrombotic (the artery to the brain becomes blocked by a clot that forms there) result in differences in the rate of incidence, mortality, and disability. Non-valvular Atrial fibrillation (AF), accompanying a global prevalence rate of around 2-3%, is often caused by hypertension, coronary heart disease, congestive heart disease. With an irregular heartbeat, heart pumps unwanted material to the brain, causing a blockage in a blood vessel resulted in a cardio-embolic stroke. The treatment of cardio-embolic stroke is shifting from the traditional Vitamin K antagonist, Warfarin, to Non-vitamin K antagonists (NOACs) in the recent decade because there was a lower risk of bleeding and strokes when patients treated with NOACs. Since the clinical demand for NOACs has been significantly growing, off-label use, especially the dosage selection regimen, has become a more critical issue in these years. In real-world studies, off-label low-dose NOACs were prescribed to more than 30% of non-valvular arrhythmia patients in Asia. Adverse effects, such as a higher risk of ischemic stroke, heart disease, and vascular death have been observed in these patients.
DOI: 10.5517/ccdc.csd.cc29ldt4
title: CCDC 2132856: Experimental Crystal Structure Determination

description: Related Article: Hai-Lei Cui|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2b6hsv
title: CCDC 2151207: Experimental Crystal Structure Determination

description: Related Article: Kentaro Okano|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2b6hvx
title: CCDC 2151209: Experimental Crystal Structure Determination

description: Related Article: Kentaro Okano|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2bj00x
title: CCDC 2160328: Experimental Crystal Structure Determination

description: Related Article: Xiao-Hui Chen, Hai-Lei Cui|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2c411m
title: CCDC 2178619: Experimental Crystal Structure Determination

description: Related Article: Jiawei Lin|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2cjqvh
title: CCDC 2190827: Experimental Crystal Structure Determination

description: Related Article: Bo Lu|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2cpfr8
title: CCDC 2195350: Experimental Crystal Structure Determination

description: Related Article: Kentaro Okano|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2czy8l
title: CCDC 2204480: Experimental Crystal Structure Determination

description: Related Article: Linghua Wang|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2d5c87
title: CCDC 2209688: Experimental Crystal Structure Determination

description: Related Article: Saleh Alsaee|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2d5vk0
title: CCDC 2210162: Experimental Crystal Structure Determination

description: Related Article: Xi Fan|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2d72j8
title: CCDC 2211339: Experimental Crystal Structure Determination

description: Related Article: Wei Liu|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2d7jt0
title: CCDC 2211782: Experimental Crystal Structure Determination

description: Related Article: Shuan-Jing Wang, Jiahui Zhang, Jing-Zan Zhang, Ruo-Nan Ning, Chen-Chen Li, Xing Xu, Min Jiang, Wen-Wei Qiu|2023|J.Med.Chem.|66|11965|doi:10.1021/acs.jmedchem.3c00601
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2dfrp9
title: CCDC 2217761: Experimental Crystal Structure Determination

description: Related Article: Sandeep Kumar, Peng Ren, Brij Mohan|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2dfrqb
title: CCDC 2217762: Experimental Crystal Structure Determination

description: Related Article: Sandeep Kumar|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.25934/00006734
title: The K18 mouse model recapitulates the transcriptomic response to acute COVID-19 Acute Respiratory Distress syndrome (ARDS) in humans

description: Mice are not naturally susceptible to infection with SARS-Cov2, the infectious agent that causes COVID-19. This is due to a structural difference in a key protein, angiotensin-converting enzyme 2 (ACE-2), which is required for cellular-entry during infection with SARS-Cov2. Since mouse models are an important resource for studying the pathophysiology of COVID-19, several genetically modified mouse models have been developed to express the human orthologue of ACE-2 (hACE-2). The K18 mouse strain is genetically modified to express hACE-2 via a cytokeratin-18 (K18) gene promoter. A recent study using the K18 mouse model reported that SARS-Cov2 infected the lungs and caused an inflammatory response similar to that observed in humans. In the current study we infected K18 mice with SARS-Cov2 to investigate the transcriptional response during the acute phase of infection, and to compare these results with the transcriptional response in humans. The results of this study will serve as an evaluation of the K18 mouse model in terms of its ability to recapitulate acute COVID-19 infection in humans.
DOI: 10.25934/00006765
title: Pandemic response COVID-19 Research Collaboration Platform

description: Project background: Over 500,000 Americans have died of COVID-19 and many more COVID-19 deaths are expected. Lessons must be learned from successes and failures in response to the pandemic. Therefore, we are conducting a pooled analysis of prior studies and its efficacy for hydroxychloroquine (and chloroquine) in hospitalized patients with COVID-19 - to provide closure for these drugs in this pandemic - we summarize relevant key studies.
Furthermore, vaccines which are being deployed, and therapeutics which have been difficult to operationalize with evidence basis, are needed. Herein, after publication of cognizance of the negative saga might help prevent repetition with other therapeutics and vaccines in the future pandemic response.
 
Vivli will be a repository for the 8 studies that will be analyzed in response to the pooling effort of the COVID-19 research collaboration platform
DOI: 10.25934/00006836
title: Smoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical Trial

description: The objective of this study is to compare medication efficacy in participants who have medical and psychiatric conditions and smoke cigarettes in the EAGLES trial. Nicotine replacement therapy and varenicline may work differently in comorbid populations in terms of ability to quit smoking, particularly as the number of comorbidities increases. We will use statistical analyses to compare these groups. Exploring how well the medications work for medically complex patients has important implications for tobacco treatment.
DOI: 10.25934/00007077
title: Dominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn’s Disease

description: Crohn’s disease (CD) is a type of inflammatory bowel disease that is characterized by periods of relapse and remission. CD affects any area of the gastrointestinal tract but is more common in the ileum and colon (1). Symptoms of CD include abdominal pain, diarrhea, fever, fatigue and weight loss. The Crohn’s Disease Activity Index (CDAI) is a tool that combines laboratory values, findings from physical examination, and three patient-reported outcomes (PROs): abdominal pain, number of daily soft/liquid stools and general well-being. 

PRO-based endpoints are now required for clinical trials for CD in place of CDAI-based endpoints (6). For example, PRO-2 remission is an endpoint that considers abdominal pain and number of daily soft/liquid stools. However, several studies have identified a disconnect between the CDAI, PROs and objective measures of disease such as endoscopy (7). Mucosal healing (MH) remains an important goal of treatment in CD. Recent post-hoc analyses have suggested that PROs at baseline and after the induction phase of treatment are not associated with one-year MH (8). However, PROs are subjective to each patient, and it is hypothesized that improvement in the most severe (dominant) PRO may have a prognostic role. The primary objective of this study is to evaluate if dominant PROs at baseline, and their improvement at the end of induction therapy, can predict longer term clinical and endoscopic outcomes at week 52.
DOI: 10.5281/zenodo.8408012
title: MarTREC Publication forBio-Inspired Stabilization of Levee Slope on Expansive Yazoo Clay at the Maritime and Multimodal Transportation Infrastructure in Mississippi

description: The link considers the data file for the MarTREC Project: Bio-Inspired Stabilization of Levee Slope on Expansive Yazoo Clay at the Maritime and Multimodal Transportation Infrastructure in Mississippi. PI: Dr. Sadik Khan Funding Agency: This material is based upon work supported by the U.S. Department of Transportation under Grant Award Number DTRT13-G-UTC50. The work was conducted through the Maritime Transportation Research and Education Center at the University of Arkansas.
DOI: 10.5281/zenodo.8408011
title: MarTREC Publication forBio-Inspired Stabilization of Levee Slope on Expansive Yazoo Clay at the Maritime and Multimodal Transportation Infrastructure in Mississippi

description: The link considers the data file for the MarTREC Project: Bio-Inspired Stabilization of Levee Slope on Expansive Yazoo Clay at the Maritime and Multimodal Transportation Infrastructure in Mississippi. PI: Dr. Sadik Khan Funding Agency: This material is based upon work supported by the U.S. Department of Transportation under Grant Award Number DTRT13-G-UTC50. The work was conducted through the Maritime Transportation Research and Education Center at the University of Arkansas.
DOI: 10.5067/terra-noaa20/ceres/cldtyphist_l3.004
title: CERES-MODIS-VIIRS and hourly geostationary cloud properties stratified by ISCCP cloud types for day and night.
DOI: 10.25934/00007158
title: Patient Reported Symptoms as Predictors of Endoscopic Improvement in Ulcerative Colitis

description: Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and ulcers to form in the colon and rectum.[1] There are several ways to assess disease severity, which include patient-reported symptoms (rectal bleeding and stool frequency), physician’s global assessment, and endoscopy. The Mayo score is comprised of all four of these components and each is scored from a scale of 0 to 3 (total score ranging from 0 to 12), with higher scores indicating more severe symptoms/disease activity. The Mayo endoscopic score is used at the time of endoscopy to assess the appearance of the colon mucosa. 

An important goal of treatment in ulcerative colitis is endoscopic improvement (EI). EI is a term used to describe improvement in the endoscopic appearance of the colon mucosa and is defined as Mayo endoscopic score of 0 or 1 in the VARISTY study (clinicaltrials.gov identifier: NCT02497469). In clinical trials, patients often undergo endoscopic assessments after a period of time since starting therapy (e.g. 8-14 weeks) and after one year to assess if EI was achieved.  

In addition to endoscopy, patient-reported symptoms (rectal bleeding and stool frequency) also reflect disease activity but are not necessarily specific to UC. Patients with UC may also have co-existing gastrointestinal conditions which may impact rectal bleeding and stool frequency. Conversely, some patients may be asymptomatic but have active endoscopic disease. Thus, patient-reported symptoms poorly correlate with the degree of inflammation as assessed by endoscopy.[2] 

The primary objective of this study is to investigate the relationship between patient-reported symptoms after completing the induction phase of treatment (week 6) and EI at one year. One year will be used as the endpoint as it was the primary endpoint used in the VARSITY study. The scientific community and patients with UC may benefit from the knowledge generated from this study. Specifically, the results of this study will provide evidence in support of strategies (e.g. reliance on symptoms, endoscopy/objective markers, or a combination of both) to assist in treatment decision-making.
DOI: 10.25934/00007159
title: Associations between steroid treatment, functional outcomes and disease milestones among subgroups of patients with Duchenne muscular dystrophy (DMD) 

description: Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder characterized by progressive deterioration in skeletal and cardiac muscles due to mutations in the dystrophin gene.[1] Globally, DMD affects approximately one in every 3,500 newborn males.[2] Initial manifestations of the disorder include progressive declines in motor function during childhood that typically culminate in complete loss of independent walking ability by adolescence.[3] Additional impacts include worsening heart and lung function, as well as a deterioration in bone health; over time, these disabling declines collectively contribute to mortality by early adulthood. The median survival for boys with DMD is 21.8 years.[4-8]

Corticosteroids are the current standard of care for patients with DMD, and have modified the disease by slowing progression of motor and lung functional decline and extending survival.[9-11] The glucocorticoids in use have been prednisone/prednisolone and deflazacort, an oxazoline derivative of prednisolone. Several comparative studies exist that examine prednisone vs. deflazacort treatment among patients with DMD.[12-14] However, additional understanding is needed about whether the comparative effectiveness of these steroids is different among subgroups of DMD patients. For instance, older vs. younger patients, patients who have been on steroids longer, and those who have more severe symptoms. This study will examine the association between steroid treatment and selected functional outcomes, body weight, and disease milestones among relevant subgroups of DMD patients. The results of this study could help inform clinical decision making around steroid options for individual patients.
DOI: 10.1184/r1/23393702.v1
title: Database categorizing 91 projects using nature-based solutions (NBS) in riverine environments across the US

description: This database categorizes 91 projects using nature-based solutions (NBS) in riverine environments across the United States. The first sheet in the workbook ('meta') describes the various categories and data types, the second sheet ('NBSDatabase') categorizes the 91 projects. These 91 projects were identified in a non-exhaustive search of Federal, State, local, and other publicly available documentation. Eight publicly available reports and websites collectively described 45 projects, while the remaining projects were sourced from individual websites or articles that described one or two projects each. For each project, we identified the following: NBS strategy or strategies installed, primary objective of the installation, total cost, year installed, project size, primary agency overseeing the project, and installation city and state. Here, project size refers to the stream length in feet influenced by the project. For some projects, details such as project cost and project size were not recorded in publicly available documents and reports. <br>
DOI: 10.25934/pr00007164
title: Evaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinoma

description: First-line treatment of metastatic renal cell carcinoma (mRCC) has changed substantially in recent years due to the introduction of immune checkpoint inhibition. Immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the “off” signal from being sent, allowing the T cells to kill cancer cells. The combination of  immune checkpoint inhibitors as well as a combination of tyrosine kinase inhibitors are nowadays standard therapies in mRCC. The success of immunotherapy is based on the induction of an anti-tumor immune response. C-reactive protein (CRP) is a substance produced by the liver in response to inflammation and is widely used as a surrogate biomarker for the assessment of systemic inflammation.

The occurrence and kinetics of systemic inflammatory response reflected by serum CRP has been implicated with treatment response in various cancer entities. Recently, Fukuda et al. described the CRP “flare-response” phenomenon defined by an early CRP increase after immunotherapy initiation with a subsequent drop below baseline. These early CRP changes appear to mirror the dynamic phase of systemic inflammation after inducing the desired antitumoral immune response on immunotherapy. We observed in a retrospective multi-center cohort with patients undergoing immunotherapy (nivolumab/ipilimumab or pembrolizumab/axitinib) as first line therapy for mRCC.

This research proposal is designed to study the relevance of the CRP flare-response phenomenon in patients treated with the combination therapy Bevacizumab/Atezolizumab versus sunitinib in the IMmotion 151 trial as predictor of patients' outcome.
DOI: 10.5517/ccdc.csd.cc1ys6yw
title: CCDC 1810739: Experimental Crystal Structure Determination

description: Related Article: Bao-Hua Song, Chen Li, Gui-Feng An|2018|J.Chem.|2018|9758197|doi:10.1155/2018/9758197
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc1ys6zx
title: CCDC 1810740: Experimental Crystal Structure Determination

description: Related Article: Bao-Hua Song, Chen Li, Gui-Feng An|2018|J.Chem.|2018|9758197|doi:10.1155/2018/9758197
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.